A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer

Trial Details

NCT ID

NCT07654400

Phase

PHASE2

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• BL-M14D1
• Atezolizumab

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Voluntarily sign the informed consent form and comply with the protocol requirements;
• No gender restriction;
• Age: ≥18 years;
• Expected survival time ≥3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.